Listen
AMELUZ (5-aminolaevulinic acid), photodynamic therapy
DERMATOLOGY - New medicinal product
Opinions on drugs -
Posted on
Mar 18 2016
Reason for request
Inclusion
No clinical benefit demonstrated over METVIXIA in the treatment of actinic keratosis on the face and scalp.
- AMELUZ has Marketing Authorisation in the treatment of mild to moderate actinic keratosis on the face and scalp (Olsen grade 1 to 2).
- The clinical data have not demonstrated any advantage, in terms of efficacy or safety, over a cream containing 160 mg/g methyl aminolevulinate (similar composition to METVIXIA).
- No comparisons between AMELUZ and cryotherapy are available.
Clinical Benefit
| Moderate |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
- |
English version
Contact Us
Évaluation des médicaments
